-+ 0.00%
-+ 0.00%
-+ 0.00%
Regeneron Pharmaceuticals To Present New And Updated Data From Hematology Portfolio And Pipeline, At ASH 2026 Annual Meeting
Share
Listen to the news

Primary analysis from a potentially pivotal trial of Ordspono® (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development program evaluating Ordspono across a broad spectrum of lymphoma settings

New data on Lynozyfic® (linvoseltamab) in R/R systemic light chain (AL) amyloidosis also to be shared in an oral presentation, also part of a clinical development program evaluating Lynzoyfic across a broad spectrum of multiple myeloma settings and precursor conditions

Additional presentations across a broad range of programs highlight next wave of innovation in blood disorders

TARRYTOWN, N.Y., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced new and updated data from its hematology portfolio and pipeline will be shared across 14 abstracts at the American Society of Hematology (ASH) 2026 Annual Meeting, taking place from December 12-15 in New Orleans. Presentations highlight progress across several treatment approaches – including bispecific antibodies and novel siRNA therapies – for a wide range of blood cancers and disorders, including lymphoma, multiple myeloma and paroxysmal nocturnal hemoglobinuria (PNH).

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending